Moleculin Biotech’s (MBRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a report published on Tuesday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright also issued estimates for Moleculin Biotech’s Q1 2026 earnings at ($1.53) EPS, Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($3.60) EPS.

MBRX has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, January 22nd. Roth Mkm reissued a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Moleculin Biotech presently has an average rating of “Hold” and a consensus target price of $22.00.

Moleculin Biotech Stock Performance

NASDAQ:MBRX opened at $2.43 on Tuesday. The firm has a market cap of $4.96 million, a price-to-earnings ratio of -0.07 and a beta of 1.73. Moleculin Biotech has a 52 week low of $1.79 and a 52 week high of $28.61. The firm has a 50-day moving average price of $3.26 and a two-hundred day moving average price of $6.88.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.